Showing 7111-7120 of 8649 results for "".
- EyePoint Fails to Reach Primary Efficacy Endpoint in Phase 2 Trial of Duravyu in NPDRhttps://modernod.com/news/eyepoint-fails-to-reach-primary-efficacy-endpoint-in-phase-2-trial-of-duravyu-in-npdr/2482265/EyePoint Pharmaceuticals announced topline results of its phase 2 PAVIA clinical trial evaluating Duravyu (vorolanib intravitreal insert), previously known as EYP-1901, in patients with non-proliferative diabetic retinopathy (NPDR). In the trial, Duravyu did not meet the pre-specified p
- World Council of Optometry and CooperVision Partner on Myopia Management Navigator Educational Resourcehttps://modernod.com/news/world-council-of-optometry-and-coopervision-partneron-myopia-management-navigator-educational-resource/2482245/With the goal of advancing myopia management as a standard of care, the World Council of Optometry (WCO) announced a partnership with CooperVision to introduce an interactive and educational resource for ey
- DigitalOptometrics Surpasses 2 Million Remote Eye Examshttps://modernod.com/news/digitaloptometrics-surpasses-2-million-remote-eye-exams/2482242/DigitalOptometrics announced it has surpassed 2 million remote comprehensive eye exams. DigitalOptometrics' remote eye exam platform is designed to allow optometrists to conduct comprehensive eye exams remotely, integrating video conferencing with remote operation of opht
- Regeneron Backs $500 Million Venture Capital Fund for Biotechnology Innovationhttps://modernod.com/news/regeneron-backs-500-million-venture-capital-fund-for-biotechnology-innovation/2482234/Regeneron Ventures announces its formation as a venture capital fund focused on promising biopharmaceutical, health care and health technology companies. The fund’s general partner will be independently managed by former Regeneron executives Jay S. Markowitz, MD, and Michael Aberman, M
- Ocular Therapeutix Names Pravin U. Dugel, MD, President and CEOhttps://modernod.com/news/ocular-therapeutix-names-pravin-u-dugel-md-president-and-ceo/2482230/Ocular Therapeutix announced that Executive Chairman, Pravin U. Dugel, MD, is assuming the roles of President and Chief Executive Officer. Dr. Dugel, who will continue to serve as a director and as Executive Chairman of Ocular, is replacing Antony Mattessich, who is stepping down f
- First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine for the Treatment of Decreased VA Under Low Light Conditions Following Keratorefractive Surgeryhttps://modernod.com/news/first-patient-enrolled-in-lynx-2-phase-3-study-evaluating-phentolamine-for-the-treatment-of-decreased-va-under-low-light-conditions-following-keratorefractive-surgery/2482227/Ocuphire Pharma announced the enrollment of the first subject in the LYNX-2 phase 3 registration study evaluating phentolamine ophthalmic solution 0.75% (PS) for the treatment of decreased visual acuity under low (mesopic) light conditions following keratorefractive surgery. The LY
- Brill Establishes Subsidiary in the United Stateshttps://modernod.com/news/brill-establishes-subsidiary-in-the-united-states/2482209/Brill, the global pharmaceutical company specializing in ophthalmology, announced the establishment of a subsidiary in the United States with headquarters in Miami, Florida, a manufacturing center in Boston, Massachusetts, and strategic locations for distributing healthcare solutions throughout t
- Glaukos Receives Permanent J-Code for iDose TRhttps://modernod.com/news/glaukos-receives-permanent-j-code-for-idose-tr/2482208/Glaukos announced that CMS has assigned a unique, permanent J-code (J7355) for iDose TR (travoprost intracameral implant) 75 mcg, a p
- Melt Pharmaceuticals Completes Stock Refinancing to Support Further Development of MELT-300https://modernod.com/news/melt-pharmaceuticals-completes-stock-refinancing-to-support-further-development-of-melt-300/2482198/Melt Pharmaceuticals announced the completion of its Series B Preferred Stock financing of approximately $24 million from new and existing investors. The capital raised will primarily support the further development of MELT-300, including the MELT-300 phase 3 program. MELT-300, a n
- SpyGlass Pharma Unveils 1-Year Data of Its Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucomahttps://modernod.com/news/spyglass-pharma-unveils-1-year-data-of-its-drug-delivery-platform-implanted-during-routine-cataract-surgery-in-eyes-with-glaucoma/2482196/SpyGlass Pharma announced 1-year follow up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ IOL-based drug delivery platform with bimatoprost at the time of cataract surgery. These data will be highlighted in a poster presentation